Mission Statement, Vision, & Core Values of Novo Nordisk A/S (NVO)

With $42.1 billion in sales in 2024, a 24.86% increase year-over-year, is it any wonder why everyone is talking about Novo Nordisk? Have you ever wondered what drives this global healthcare giant, beyond just the numbers? What are the guiding principles that shape its mission, vision, and core values, and how do these translate into real-world impact?

Dive in to discover how this company, with over 77,000 employees in 80 offices globally, strives to 'drive change to defeat serious chronic diseases,' and how its commitment to innovation, sustainability, and ethical practices shapes its identity and goals.

Novo Nordisk A/S (NVO) An Overview of

Novo Nordisk A/S, a global healthcare company, has been dedicated to driving change to defeat diabetes and other serious chronic diseases such as obesity, rare blood, and endocrine disorders. Founded in 1923, the company is headquartered in Bagsvaerd, Denmark. Novo Nordisk delivers innovative medicines and solutions to patients in over 168 countries. As of April 2025, the company continues to expand its reach and impact through strategic partnerships and a strong focus on research and development.

The company's product portfolio includes a range of treatments for diabetes, obesity, and other serious chronic conditions. Key products include:

• Ozempic and Rybelsus: Medications for type 2 diabetes.
• Wegovy: A treatment for obesity.
• Insulin products: A variety of insulin formulations for diabetes management.
• Hormone therapy products: Treatments for growth disorders and other endocrine conditions.

Novo Nordisk reported a record-breaking revenue of DKK 232.3 billion for the full year of 2024, marking a 22% sales increase compared to the previous year. This growth was primarily driven by increased sales of diabetes and obesity care products. Sales within North America surged by 34%, while international operations saw a growth of 16%. The success of products like Ozempic and Wegovy significantly contributed to these impressive financial results, solidifying Novo Nordisk's position in the pharmaceutical industry.

Novo Nordisk stands as a leader in the healthcare industry, particularly renowned for its innovative treatments in diabetes and obesity care. The company's commitment to research and development, coupled with its global presence, has enabled it to achieve significant milestones. Want to understand why Novo Nordisk is so successful? Find out more here: Exploring Novo Nordisk A/S (NVO) Investor Profile: Who’s Buying and Why?

Novo Nordisk A/S (NVO) Mission Statement

The mission of Novo Nordisk is to 'drive change to defeat diabetes and other serious chronic diseases, such as obesity and rare blood and endocrine disorders'. This mission reflects a commitment to pioneering scientific breakthroughs, expanding access to medicines, and working towards prevention and ultimately, cures for these diseases.

The company's dedication extends beyond just treating illnesses. It encompasses a broader impact on society and healthcare systems by focusing on patient-centric approaches, prioritizing the needs and preferences of individuals in developing treatments and providing support.

Let's explore the key components of Novo Nordisk's mission statement:

• Drive Change: This signifies a proactive approach to transforming diabetes care and treatment.
• Defeat Diabetes and Other Serious Chronic Diseases: This indicates a commitment to combating major health challenges beyond diabetes, including obesity and rare disorders.
• Improve Lives: This highlights the patient-centric focus of the company, aiming to enhance the well-being of individuals affected by chronic conditions.

Novo Nordisk's mission is supported by core values that guide the company's culture, operations, and interactions with stakeholders. These values include:

• Integrity: Upholding the highest ethical standards in all aspects of the business.
• Innovation: Investing in research and development to discover new and improved treatments and solutions.
• Quality: Providing high-quality products and services that make a real difference in patients' lives.
• Respect: Valuing diversity and treating everyone with respect.
• Responsibility: Ensuring financial, environmental, and social accountability.

In 2024, Novo Nordisk's dedication to its mission and values translated into strong financial performance. Sales increased by 25% in Danish kroner and 26% at constant exchange rates, reaching USD 42.1 billion. This growth was primarily driven by increased demand for GLP-1-based diabetes and obesity treatments. The company's operating profit also increased by 25% in Danish kroner and 26% at constant exchange rates to USD 18.6 billion.

The company is also focused on open innovation, sharing molecular compounds for preclinical research and creating innovation ecosystems to accelerate new medicine discovery and better digital health solutions.

Novo Nordisk is dedicated to creating value for patients by changing diabetes care, its perception, and its future. This commitment extends to research, education, public policy, and humanitarian efforts.

The company's long-term ambition includes providing access to affordable diabetes care for vulnerable patients in every country. Novo Nordisk also aims to prevent more than 100 million people from getting type 2 diabetes by 2045.

To effectively manage its rapid expansion, Novo Nordisk invests in leadership development programs to maintain its corporate culture, known as the Novo Nordisk Way.

For more insights into Novo Nordisk, explore Exploring Novo Nordisk A/S (NVO) Investor Profile: Who’s Buying and Why?

Novo Nordisk A/S (NVO) Vision Statement

Novo Nordisk's mission is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and endocrine disorders. This is achieved by pioneering scientific breakthroughs, expanding access to medicines, and working to prevent and ultimately cure disease.

The company's strategic aspirations are organized around three interdependent priorities:

• Innovate to lead in disease areas
• Transform how care is delivered
• Expand access to more patients

These priorities guide Novo Nordisk in its commitment to sustainable business practices through the Triple Bottom Line, ensuring financial, environmental, and social responsibility. For instance, in 2024, Novo Nordisk allocated a significant portion of its revenue, approximately DKK 28.9 billion, to R&D, demonstrating its commitment to innovation.

Novo Nordisk's core values, which include being a responsible business, also influence its strategic decisions. The company aims to achieve zero CO2 emissions from operations and transport by 2045, showcasing its dedication to environmental sustainability. Exploring Novo Nordisk A/S (NVO) Investor Profile: Who’s Buying and Why?

Further, the company's commitment to access extends beyond medicine, as demonstrated by initiatives to support vulnerable patient populations. In 2023, Novo Nordisk supported 2.6 million vulnerable people through various programs, emphasizing its social responsibility.

Innovate to Lead in Disease Areas

Novo Nordisk allocates significant resources to research and development to maintain its leadership in diabetes care and expand into other serious chronic diseases. In 2024, the company invested DKK 28.9 billion in R&D, focusing on developing innovative treatments and delivery systems. This commitment is evident in their pipeline of new products and advancements in existing treatments. For example, the development of new GLP-1 receptor agonists and insulin formulations aims to provide better glycemic control and improved patient outcomes. The company's R&D efforts also extend to obesity treatments, reflecting the increasing global prevalence of obesity and its related health complications.

Transform How Care is Delivered

Transforming care delivery involves leveraging digital health solutions and partnerships to improve patient access and adherence to treatments. Novo Nordisk is actively involved in developing digital platforms and apps that provide personalized support and monitoring for patients. These tools help patients manage their conditions more effectively and enable healthcare professionals to make informed decisions. Furthermore, the company collaborates with healthcare providers and organizations to implement integrated care models that streamline treatment pathways and enhance patient experiences. This includes initiatives such as telemedicine programs and remote monitoring devices, which are particularly beneficial for patients in underserved areas.

Expand Access to More Patients

Expanding access to medicines is a critical component of Novo Nordisk's vision, particularly in low- and middle-income countries. The company implements various strategies to ensure that its products are affordable and accessible to patients who need them the most. This includes tiered pricing models, partnerships with local governments and NGOs, and participation in global health initiatives. For example, Novo Nordisk has programs in place to provide insulin at reduced costs in several countries, addressing the challenges of affordability and availability. These efforts are crucial in reducing the global burden of diabetes and other chronic diseases.

Novo Nordisk A/S (NVO) Core Values of

At Company, the core values serve as guiding principles that shape the company's culture, strategy, and interactions with stakeholders. These values reflect Company's commitment to making a positive impact on people's health and well-being, while also driving sustainable business growth. Company's dedication to these values is evident in its various initiatives and programs aimed at addressing unmet medical needs, promoting ethical business practices, and fostering a culture of innovation and collaboration. Learn more about Company's financial health: Breaking Down Novo Nordisk A/S (NVO) Financial Health: Key Insights for Investors

Value 1: Innovation to Improve Patient Outcomes

Company places a high priority on innovation as a means to improve patient outcomes and address unmet medical needs. This commitment is reflected in the company's substantial investment in research and development, which amounted to DKK 46.7 billion in 2024, representing 15.8% of sales. This investment fuels the development of new and improved treatments for diabetes, obesity, and other serious chronic diseases. Company's approach to innovation extends beyond scientific breakthroughs to include new ways of delivering care and supporting patients in their daily lives. For example, Company has developed digital health solutions that provide personalized support and education to people living with diabetes.

• In 2024, Company allocated DKK 46.7 billion to R&D, demonstrating its dedication to pioneering new treatments.
• The company's R&D expenditure accounted for 15.8% of its sales, highlighting the significance of innovation in its business strategy.

Value 2: Integrity and Ethical Conduct

Company is committed to conducting its business with the highest standards of integrity and ethical conduct. This commitment is embedded in the company's Code of Conduct, which outlines the principles and expectations that guide employees' behavior. Company also has a comprehensive compliance program in place to ensure that its activities are in accordance with all applicable laws and regulations. The company's commitment to integrity extends to its interactions with healthcare professionals, patients, and other stakeholders. Company is transparent about its research and clinical trial data, and it engages in responsible marketing practices.

• Company adheres to a strict Code of Conduct, ensuring ethical behavior across all operations.
• A comprehensive compliance program is in place to maintain adherence to laws and regulations.

Value 3: Focus on Long-Term Sustainability

Company recognizes the importance of operating in a sustainable manner that minimizes its environmental impact and contributes to a healthier planet. This commitment is reflected in the company's ambitious environmental targets, such as achieving carbon neutrality in its operations by 2030. Company is also working to reduce its water consumption, waste generation, and greenhouse gas emissions throughout its value chain. The company's sustainability efforts extend beyond environmental stewardship to include social responsibility. Company is committed to promoting diversity and inclusion in its workforce, supporting local communities, and ensuring access to its medicines for patients in need.

• Company aims to achieve carbon neutrality in its operations by 2030, demonstrating a strong commitment to environmental sustainability.
• The company is actively reducing water consumption, waste, and greenhouse gas emissions across its value chain.

Value 4: Collaboration and Partnership

Company recognizes that collaboration and partnership are essential for achieving its mission of improving patient outcomes. The company actively seeks to collaborate with other organizations, including academic institutions, research organizations, and patient advocacy groups. These collaborations enable Company to leverage external expertise and resources to accelerate innovation and expand its reach. Company also partners with healthcare providers and payers to improve access to its medicines and ensure that patients receive the best possible care. For example, Company has established partnerships with several organizations to address the growing problem of obesity.

• Company actively collaborates with academic institutions, research organizations, and patient advocacy groups to enhance innovation.
• Partnerships with healthcare providers and payers aim to improve access to medicines and patient care.

Value 5: Respect and Opportunity

Company is committed to creating a workplace where all employees feel respected, valued, and have the opportunity to reach their full potential. This commitment is reflected in the company's diversity and inclusion policies, which promote equal opportunities for all employees regardless of their background or identity. Company also invests in employee training and development to help its employees grow and advance in their careers. The company's commitment to respect and opportunity extends beyond its own workforce to include its suppliers and partners. Company expects its suppliers to adhere to high standards of labor practices and human rights.

• Company's diversity and inclusion policies ensure equal opportunities for all employees.
• Investments in training and development support employee growth and career advancement.